0001104659-21-054690.txt : 20210426 0001104659-21-054690.hdr.sgml : 20210426 20210426070513 ACCESSION NUMBER: 0001104659-21-054690 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210426 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210426 DATE AS OF CHANGE: 20210426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001137883 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 207273918 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36641 FILM NUMBER: 21851529 BUSINESS ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 201-488-0460 MAIL ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC DATE OF NAME CHANGE: 20041122 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC DATE OF NAME CHANGE: 20030827 FORMER COMPANY: FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC DATE OF NAME CHANGE: 20010409 8-K 1 tm2111643d2_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2021

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36641		20-7273918
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

1325 Avenue of Americas, 28th Floor
New York, NY	10019
(Address of principal executive offices)	(Zip Code)

(201) 488-0460

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00005 par value

BCLI

NASDAQ Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On April 26, 2021, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing its financial and operating results for the quarter ended March 31, 2021. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The Company will host a live conference call and webcast at 8:00 am ET on Monday, April 26, 2021 to discuss first quarter 2021 financial results and business progress. A live webcast of the conference call may be accessed by visiting the Investors & Media section of the Company’s website at https://ir.brainstorm-cell.com.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press Release issued by the Company on April 26, 2021, furnished hereto.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRAINSTORM CELL THERAPEUTICS INC.


Date: April 26, 2021	By:	/s/ Chaim Lebovits
		Chaim Lebovits
		Chief Executive Officer

EX-99.1 2 tm2111643d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update

Positive Phase 2 data demonstrate the potential of NurOwn® as a treatment for progressive MS

Regulatory strategy progressing to advance NurOwn’s approval in ALS

Conference call and webcast at 8:00 a.m. Eastern Time today

NEW YORK, April 26, 2021 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2021 and provided a corporate update.

“In the first quarter we were excited to announce positive top line data from our Phase 2 trial evaluating NurOwn® as a treatment for progressive multiple sclerosis (MS). These data expand the body of evidence supporting the NurOwn® technology platform across neurodegenerative diseases,” said Chaim Lebovits, Chief Executive Officer of BrainStorm. “In our ALS program, we intend to submit a manuscript for peer review shortly and are delivering scientific presentations. We are currently in active discussions with various experts including principal investigators, ALS physicians, statisticians, regulatory advisors as well as patient advocacy groups, in addition to potential strategic partners. Based on all feedback received, we will assess the best path forward to enable patients access to NurOwn including FDA BLA submission and/or other regulatory and business options.”

First Quarter 2021 Corporate Highlights

·

Announced positive top-line data from the open label Phase 2 trial evaluating NurOwn® as a treatment for progressive multiple sclerosis (MS). The trial achieved the primary endpoint of safety and demonstrated clinically meaningful improvements in multiple endpoints.

o

Consistent improvement across all functional measures were observed, in comparison to the matched clinical cohort from the Comprehensive Longitudinal Investigations in MS at the Brigham & Woman's Hospital (CLIMB Study).

o

Pre-specified responder analysis demonstrated consistent improvements in functional measures including walking, vision and cognition. These improvements were not seen in any of the matched CLIMB patients.

o

Consistent increases in delivered neurotrophic factors and a reduction across key inflammatory biomarkers were observed.

·

Following FDA feedback on the Phase 3 NurOwn ALS clinical data, and enacting FDA advice, we have made great progress in the important steps needed to develop and then act on our regulatory strategy. These include submission of a manuscript for a peer-reviewed publication of NurOwn’s Phase 3 clinical trial results and conducting ongoing consultations with key ALS stakeholders in the U.S. and other jurisdictions confirming the strength of the data and providing feedback and valuable guidance on next steps.

·

Published data from a preclinical study showing that intrathecal administration of NurOwn derived exosomes significantly improved lung function and histology in a mouse model of acute respiratory distress syndrome (ARDS), a type of respiratory failure frequently associated with COVID-19. The study, entitled, "MSC-NTF (NurOwn) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model," was published in the peer-reviewed journal Stem Cell and Research Therapy.

Presented at the following investor conferences:

·

10^th Annual SVB Leerink Global Healthcare Conference

Cash and Liquidity as of March 31, 2021

Total available funding as of March 31, 2021, which includes cash, cash equivalents and short-term bank deposits of approximately $40.0 million, an untapped ATM capacity of approximately $16.0 million, as well as remaining non-dilutive funding from grants, amounts to approximately $57.0 million.

Financial Results for the Three Months Ended March 31, 2021

Cash, cash equivalents, and short-term bank deposits were approximately $40.0 million as of March 31, 2021, compared to approximately $42.0 million on December 31, 2020.

Research and development expenses, net for the three months ended March 31, 2021 and 2020 were approximately $4.3 million and $5.9 million, respectively.

Excluding participation from IIA and CIRM under the grants and proceeds received under the hospital exemption regulatory pathway, research and development expenses decreased by approximately $2.3 million from $7.1 million in the first quarter of 2020 to $4.8 million in the first quarter of 2021.

General and administrative expenses for the three months ended March 31, 2021 and 2020 were approximately $2.6 million and $2.4 million, respectively.

Net loss for the three months ended March 31, 2021 was approximately $6.6 million, as compared to a net loss of approximately $8.1 million for the three months ended March 31, 2020.

Net loss per share for the three months ended March 31, 2021 and 2020 was $0.19 and $0.32, respectively.

Conference Call & Webcast

Monday, April 26, 2021 at 8:00 a.m. Eastern Time

From the U.S.:	877-407-9205
International:	201-689-8054
Webcast URL:	https://www.webcaster4.com/Webcast/Page/2354/40513

Replays, available through May 10, 2021

From the U.S.:	877-481-4010
International:	919-882-2331
Replay Passcode:	40513

About NurOwn®

The NurOwn^® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn^® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

For more information, visit the company's website at www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future NurOwn^® manufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwn^®treatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn^® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwn^® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contacts
Investor Relations:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Phone: +1 646-465-1138
cdavis@lifesciadvisors.com

Media:
Paul Tyahla
SmithSolve
Phone: + 1.973.713.3768
Paul.tyahla@smithsolve.com

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

(Except share data)

		March 31,				December 31,
		2021				2020
		U.S. $ in thousands
ASSETS

Current Assets:
Cash and cash equivalents		$	35,933			$	37,829
Short-term deposit (Note 4)			4,114				4,107
Other accounts receivable			255				304
Prepaid expenses and other current assets (Note 5)			728				1,002
Total current assets			41,030				43,242

Long-Term Assets:
Prepaid expenses and other long-term assets			27				26
Operating lease right of use asset (Note 6)			6,426				6,872
Property and Equipment, Net			1,088				1,119
Total Long-Term Assets			7,541				8,017

Total assets		$	48,571			$	51,259

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable		$	2,552			$	5,417
Accrued expenses			1,748				1,261
Operating lease liability (Note 6)			2,299				2,655
Other accounts payable			1,592				1,900
Total current liabilities			8,191				11,233

Long-Term Liabilities:
Operating lease liability (Note 6)			4,179				4,562
Total long-term liabilities			4,179				4,562

Total liabilities		$	12,370			$	15,795

Stockholders’ Equity:
Stock capital: (Note 7)			12				12
Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at March 31, 2021 and December 31, 2020 respectively; Issued and outstanding: 36,318,561 and 35,159,977 shares at March 31, 2021 and December 31, 2020 respectively.
Additional paid-in-capital			192,054				184,655
Treasury stocks			(116	)			(116	)
Accumulated deficit			(155,749	)			(149,087	)
Total stockholders’ equity			36,201				35,464

Total liabilities and stockholders’ equity		$	48,571			$	51,259

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

U.S. dollars in thousands

(Except share data)

		Three months ended
		March 31,
		2021				2020
		Unaudited
Operating expenses:

Research and development, net (Note 8)		$	4,341			$	5,948
General and administrative			2,588				2,360

Operating loss			(6,929	)			(8,308	)

Financial income, net			267				194

Net loss		$	(6,662	)		$	(8,114	)

Basic and diluted net loss per share from continuing operations		$	(0.19	)		$	(0.32	)

Weighted average number of shares outstanding used in computing basic and diluted net loss per share			35,791,309				28,423,837

EX-101.SCH 3 bcli-20210226.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bcli-20210226_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bcli-20210226_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2111643d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001137883 2021-02-26 2021-02-26 iso4217:USD shares iso4217:USD shares 0001137883 false 8-K 2021-04-26 Brainstorm Cell Therapeutics Inc. DE 001-36641 20-7273918 1325 Avenue of Americas 28th Floor New York NY 10019 201 488-0460 false false false false Common Stock, $0.00005 par value BCLI NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 26, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 26, 2021
Entity File Number	001-36641
Entity Registrant Name	Brainstorm Cell Therapeutics Inc.
Entity Central Index Key	0001137883
Entity Tax Identification Number	20-7273918
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1325 Avenue of Americas
Entity Address, Address Line Two	28th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	201
Local Phone Number	488-0460
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.00005 par value
Trading Symbol	BCLI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://brainstorm-cell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2111643d2_8k.htm bcli-20210226.xsd bcli-20210226_lab.xml bcli-20210226_pre.xml tm2111643d2_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2111643d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2111643d2_8k.htm" ] }, "labelLink": { "local": [ "bcli-20210226_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bcli-20210226_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bcli-20210226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bcli", "nsuri": "http://brainstorm-cell.com/20210226", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2111643d2_8k.htm", "contextRef": "From2021-02-26to2021-02-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://brainstorm-cell.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2111643d2_8k.htm", "contextRef": "From2021-02-26to2021-02-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://brainstorm-cell.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-054690-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-054690-xbrl.zip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end